Emily Luisa Hill, the Chief Financial Officer of Replimune Group, Inc., recently executed a transaction involving the sale of 14,709 shares of the company’s common stock. This sale was made to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs). The transaction occurred on November 16, 2026, and was reported on November 18, 2026.

This event is significant as it underscores the financial activities of executives within the biotech sector, particularly in a company like Replimune that specializes in biological products. The sale was conducted under an irrevocable “sell to cover” provision, meaning it was not a discretionary sale but rather a necessary action to meet tax obligations.

Background

Replimune Group, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment. The company operates under the SIC classification for Biological Products (No Diagnostic Substances) [2836]. Replimune is publicly traded and is known for its commitment to advancing cancer treatment through its unique product offerings.

What the Filing Says

"Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the vesting of the Reporting Person's Restricted Stock Units."

The filing indicates that the shares were sold at a weighted average price of $21.60, with individual transactions occurring at prices ranging from $21.59 to $21.60 per share. Following this transaction, Hill retains ownership of 201,143 shares of Replimune's common stock.

Impact

This transaction may affect various stakeholders, including Replimune's investors and employees, by highlighting the financial responsibilities of executives and the mechanisms in place for managing stock-based compensation. Transparency in such transactions is crucial for maintaining investor confidence, especially in the competitive biotech industry.

What's Next

The filing does not say what happens next.